DOCSLIB.ORG

Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity molecules Article Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and Cytotoxicity Martin Krátký 1,*, Magdaléna Dzurková 2, Jiˇrí Janoušek 3, Klára Koneˇcná 4, František Trejtnar 3, JiˇrinaStolaˇríková 5 and Jarmila Vinšová 1 1 Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; [email protected] 2 Department of Chemistry, Faculty of Science, J. E. Purkinje University, Ceskˇ é mládeže 8, 400 96 Ústí nad Labem, Czech Republic; [email protected] 3 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; [email protected] (J.J.); [email protected] (F.T.) 4 Department of Biological and Medical Sciences, Faculty of Pharmacy, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; [email protected] 5 Laboratory for Mycobacterial Diagnostics and Tuberculosis, Regional Institute of Public Health in Ostrava, Partyzánské námest˘ í 7, 702 00 Ostrava, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-495067343; Fax: +420-495067166 Received: 25 August 2017; Accepted: 13 September 2017; Published: 19 September 2017 Abstract: The resistance among microbes has brought an urgent need for new drugs. Thus, we synthesized a series of Schiff bases derived from the sulfa drug sulfadiazine and various salicylaldehydes. The resulting 4-[(2-hydroxybenzylidene)amino]-N -(pyrimidin-2-yl)benzene-sulfonamides were characterized and evaluated against Gram-positive and Gram-negative bacteria, yeasts, moulds, Mycobacterium tuberculosis, nontuberculous mycobacteria (M. kansasii, M. avium) and their cytotoxicity was determined. Among bacteria, the genus Staphylococcus, including methicillin-resistant S. aureus, showed the highest susceptibility, with minimum inhibitory concentration values from 7.81 µM. The growth of Candida sp. and Trichophyton interdigitale was inhibited at concentrations starting from 1.95 µM. 4-[(2,5-Dihydroxybenzylidene)amino]-N-(pyrimidin-2-yl)-benzenesulfonamide was identified as the most selective Schiff base for these strains with no apparent cytotoxicity and a selectivity index higher than 16. With respect to M. tuberculosis and M. kansasii that were inhibited within the range of 8 to 250 µM, unsubstituted 4-[(2-hydroxy-benzylidene)amino]-N-(pyrimidin-2-yl)benzenesulfonamide meets the selectivity requirement. In general, dihalogenation of the salicylic moiety improved the antibacterial and antifungal activity but also increased the cytotoxicity, especially with an increasing atomic mass. Some derivatives offer more advantageous properties than the parent sulfadiazine, thus constituting promising hits for further antimicrobial drug development. Keywords: antibacterial activity; antifungal activity; antimycobacterial activity; cytotoxicity; Schiff bases; sulfadiazine; sulfonamides 1. Introduction Schiff bases are condensation products of primary (aromatic) amines with aldehydes or ketones carrying the azomethine (imino) moiety (-CR=N-). They are considered versatile pharmacophores for various pharmacological activities where the azomethine group has been demonstrated to be critical to the bioactivity. For example, Schiff bases, whether of natural or non-natural origin, have exhibited promising antibacterial, antitubercular, antifungal, antiparasitic, antiviral, antioxidant, anticancer, Molecules 2017, 22, 1573; doi:10.3390/molecules22091573 www.mdpi.com/journal/molecules Molecules 2017, 22, 1573 2 of 15 analgesic, anti-inflammatory properties etc. [1–3]. Altogether, they represent very frequently used and useful scaffold in medicinal chemistry. SchiffMolecules 2017 bases, 22, 1573 of substituted salicylaldehydes (2-hydroxybenzaldehydes) are well-known2 of 15 antimicrobialMolecules 2017 agents, 22, 1573in “free” form or as ligands in metallic complexes [4–7]. Similar biological2 of 15 Schiff bases of substituted salicylaldehydes (2-hydroxybenzaldehydes) are well-known action have been reported for Schiff bases of various sulfonamides [4,8,9]. In addition, antimicrobialSchiff bases agents of in “free”substituted form orsalicylaldehyde as ligands in metallics (2-hydroxybenzaldehydes) complexes [4–7]. Similar arebiological well-known action cotrimoxazole, sulfamethoxazole and sulfadiazine (1, SDZ, Figure1) have exhibited activity against haveantimicrobial been reported agents infor “free” Schiff form bases or asof ligands various in su metalliclfonamides complexes [4,8,9]. [4–7]. In addition, Similar biological cotrimoxazole, action Mycobacterium tuberculosis [10] as well as nontuberculous (atypical) mycobacteria (NTM) [11] at sulfamethoxazolehave been reported and for sulfadiazine Schiff bases (1 , ofSDZ, various Figure su 1)lfonamides have exhibited [4,8,9]. activity In addition, against cotrimoxazole,Mycobacterium clinicallytuberculosissulfamethoxazole achievable [10] as concentrations welland sulfadiazineas nontuberculous after (1, SDZ, administration (atypical) Figure 1)mycobacteria haveper exhibited os. To (NTM) the activity best [11] of atagainst ourclinically knowledge, Mycobacterium achievable there is no reportconcentrationstuberculosis about [10] an after identicalas well administration as propertynontuberculous ofper sulfathiazole,os. (atypical)To the best mycobacteria usedof our now knowledge,only (NTM) topically, there[11] at is clinically no or otherreport achievable sulfonamides.about an El-Baradieidenticalconcentrations reported property after [ 12of administration] sulfathiazole, an antibacterial per used os. activityTonow the only best of oftopically, a our SDZ-based knowledge, or other Schiff theresulfonamides. base is no with report El-Baradie unsubstituted about an salicylaldehyde.reportedidentical [12]property Itan exhibited antibacterial of sulfathiazole, minimum activity ofused inhibitory a SDZ-ba now onlysed concentrations Schiff topically, base withor (MICs)other unsubs sulfonamides. oftituted 100–250 salicylaldehyde.µ g/mLEl-Baradie for both It exhibited minimum inhibitory concentrations (MICs) of 100–250 µg/mL for both Gram-positive Gram-positivereported [12] and an antibacterial Gram-negative activity bacteria. of a SDZ-ba Thesed Schiff Schiff base base derived with unsubs fromtituted 5-bromosalicylaldehyde salicylaldehyde. and Gram-negative bacteria. The Schiff base derived from 5-bromosalicylaldehyde exhibited a exhibitedIt exhibited a broad minimum spectrum inhibitory of concentrations antibacterial (MICs) and of antifungal 100–250 µg/mL properties for both Gram-positive [13]. Isosteric broad spectrum of antibacterial and antifungal properties [13]. Isosteric 4-(5-chloro-2- 4-(5-chloro-2-hydroxybenzylideneamino)-and Gram-negative bacteria. The Schiff Nbase-(pyrimidin-2-yl)benzenesulfonamide derived from 5-bromosalicylaldehyde (exhibited2c, Figure a 2) hydroxybenzylideneamino)-broad spectrum of antibacterialN-(pyrimidin-2-yl)benzenesulfonamide and antifungal properties ([13].2c, Figure Isosteric 2) showed 4-(5-chloro-2- activity showed activity against Staphylococcus aureus, including a methicillin-resistant strain (MRSA), againsthydroxybenzylideneamino)- Staphylococcus aureusN, -(pyrimidin-2-yl)benzenesulfonamideincluding a methicillin-resistant strain (2c (MRSA),, Figure M.2) showedtuberculosis activity and M. tuberculosis Mycobacterium avium µ Mycobacteriumagainst Staphylococcusand avium (MIC aureus values, including within thea(MIC methicillin-resistant range values of 125–250 within µM) strain the whereas range (MRSA), it of caused 125–250M. tuberculosis a significantlyM) whereasand it causedhigherMycobacterium a significantlyinhibition avium of Mycobacterium higher(MIC values inhibition withinkansasii of the strainsMycobacterium range (8–32 of 125–250 µM) kansasii [4]. µM) whereasstrains (8–32it causedµM) a significantly [4]. higher inhibition of Mycobacterium kansasii strains (8–32 µM) [4]. FigureFigure 1.1. Sulfadiazine 1.1 . Figure 1. Sulfadiazine 1. Keeping in mind these facts, we decided to combine two well-established pharmacophores for Keeping in mind these facts, we decided to combine two well-established pharmacophores for antimicrobialKeeping activity,in mind sulfadiazine these facts, andwe decidedsalicylaldehyd to combinee, into two one well-establishedmolecular Schiff basepharmacophores entity (Figure for 2) antimicrobial activity, sulfadiazine and salicylaldehyde, into one molecular Schiff base entity (Figure2) andantimicrobial to screen activity, systematically sulfadiazine their and antimicrobial salicylaldehyd ande, into cytotoxic one molecular properties. Schiff In base our entity study (Figure [4], the 2) and to screen systematically their antimicrobial and cytotoxic properties. In our study [4], the activities activitiesand to screen of sulfadiazine systematically amides their and antimicrobialimines based onand the cytotoxic salicylic properties.scaffold were In comparableour study [4],against the of sulfadiazinetheactivities majority of amides sulfadiazineof mycobacterial and iminesamides strains basedand andimines on drug-susceptible the based salicylic on the scaffold salicylic Staphylococcus were scaffold comparable aureus were, butcomparable further against research theagainst majority of mycobacterialdiscoveredthe majority that of strains mycobacterial the amides and drug-susceptible are strains significantly and drug-susceptible
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al
    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
    [Show full text]
  • Pyrimethamine
    Canterbury District Health Board Neonatal Services PYRIMETHAMINE Trade Name Daraprim (GlaxoSmithKlyne) Class Antiparasitic/antimalarial agent Mechanism of Action Inhibits parasitic dihydrofolate reductase resulting in inhibition of tetrahydrofolic acid synthesis Indications Congenital toxoplasmosis (Used in combination with sulfadiazine) Contraindications Known megaloblastic anaemia Supplied As Pyrimethamine suspension 1mg/mL (prepared by pharmacy) Dilution None required Dosage 1mg/kg/dose If the patient has difficulty tolerating pyrimathamine give each dose with a feed to reduce the incidence of vomiting Interval Once daily for the first 6 months, then Three times a week for the second 6 months Administration Oral Compatible With N/A Incompatible With N/A Interactions Pyrimethamine reduces the anti-epileptic effect of phenytoin Antifolate effects are increased when pyrimethamine is given in combination with sulphonamides, trimethoprim, zidovudine or methotrexate. Folic Acid may reduce the anti-parasitic effect of pyrimethamine and also increase the risk of pyrimethamine induced bone marrow suppression , for these reasons folinic acid is used to counteract the antifolate effect of pyrimethamine. Avoid brands of sunblock that contain PABA as this may reduce the effectiveness of sulfadiazine. Monitoring Full blood count Stability 30 days at 2 – 8 oC Storage In the fridge Adverse Reactions Skin rash (including Stevens Johnson Syndrome), nausea, vomiting, diarrhoea, blood dyscrasias, raised AST, sensory neuropathy Metabolism 15-40% metabolised by liver, approx 60% of dose excreted as Pyrimethamine Printed copies are not controlled and may not be the current version in use Ref.236799 Authorised by: Clinical Director Neonatal Page 1 of 2 March 2016 Canterbury District Health Board Neonatal Services unchanged drug by kidneys.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Nitroaromatic Antibiotics As Nitrogen Oxide Sources
    Review biomolecules Nitroaromatic Antibiotics as Nitrogen Oxide Sources Review Allison M. Rice, Yueming Long and S. Bruce King * Nitroaromatic Antibiotics as Nitrogen Oxide Sources Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; Allison M. Rice , Yueming [email protected] and S. Bruce (A.M.R.); King [email protected] * (Y.L.) * Correspondence: [email protected]; Tel.: +1-336-702-1954 Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; [email protected]: Nitroaromatic (A.M.R.); [email protected] antibiotics (Y.L.) show activity against anaerobic bacteria and parasites, finding * Correspondence: [email protected]; Tel.: +1-336-702-1954 use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the Abstract: Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding usedevelopment in the treatment of new of Heliobacter treatments pylori forinfections, these conditio tuberculosis,ns, the trichomoniasis, associated toxicity human Africanand lack of clear trypanosomiasis,mechanisms of action Chagas have disease limited and their leishmaniasis. therapeutic Despite development. this activity Nitroaro and a clearmatic need antibiotics for require thereductive development bioactivation of new treatments for activity for theseand this conditions, reductive the associatedmetabolism toxicity can convert
    [Show full text]
  • Antibiotic Resistance and Trend of Urinary Pathogens in General Outpatients from a Major Urban City
    Clinical Urology Resistance of Urinary Pathogens in Outpatients International Braz J Urol Vol. 33 (1): 42-49, January - February, 2007 Antibiotic Resistance and Trend of Urinary Pathogens in General Outpatients from a Major Urban City Carlos R. Kiffer, Caio Mendes, Carmen P. Oplustil, Jorge L. Sampaio Section of Microbiology, Fleury Institute, Sao Paulo, SP, Brazil ABSTRACT Objective: We assessed the antimicrobial resistance patterns of pathogens responsible for urinary tract infections (UTI) in outpatients in São Paulo, Brazil, as well as the Escherichia coli antimicrobial resistance trend. Materials and Methods: Outpatients urine cultures were collected from January 2000 to December 2003. Statistical analy- sis considered positive results for one bacterial species with colony count ≥ 100,000 CFU/mL. Stratification was done on age group and gender. Statistical tests used included chi-square and the chi-square test for trend to evaluate differences between susceptibility rates among age groups and ordering in the E. coli resistance rates per year, respectively. Results: There were 37,261 positive results with Enterobacteriaceae isolated in 32,530 (87.3%) and Gram-positive cocci in 2,570 (6.9%) cultures. E. coli had the highest prevalence (71.6%). Susceptibility tests were performed in 31,716 cultures. E. coli had elevated resistance rates (> 30%) to ampicillin, trimethoprim-sulfamethoxazole, and tetracycline. Significant differences between age groups and ordering among years were observed. Conclusions: The use of trimethoprim-sulfamethoxazole is precluded in the population studied due to elevated resistance rates (> 30%) among most prevalent pathogens. Significant resistance rate differences among age groups and years were observed, particularly for fluoroquinolones. Fluoroquinolones should be used with caution.
    [Show full text]
  • Gene-Drug Interactions and the Evolution of Antibiotic Resistance
    Gene-Drug Interactions and the Evolution of Antibiotic Resistance The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Palmer, Adam Christopher. 2012. Gene-Drug Interactions and the Evolution of Antibiotic Resistance. Doctoral dissertation, Harvard University. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10436292 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA © - Adam Christopher Palmer All rights reserved. Professor Roy Kishony Adam Christopher Palmer Gene-drug interactions and the evolution of antibiotic resistance Abstract The evolution of antibiotic resistance is shaped by interactions between genes, the chemical environment, and an antibiotic's mechanism of action. This thesis explores these interactions with experiments, theory, and analysis, seeking a mechanistic understanding of how different interactions between genes and drugs can enhance or constrain the evolution of antibiotic resistance. Chapter 1 investigates the effects of the chemical decay of an antibiotic. Tetracycline resistant and sensitive bacteria were grown competitively in the presence of tetracycline and its decay products. Antibiotic decay did not only remove selection for resistance, but long- lived decay products favored tetracycline sensitivity by inducing costly drug efflux pumps in the resistant strain. Selection against resistance by antibiotic-related compounds may contribute to the coexistence of drug-sensitive and resistant bacteria in nature. Chapter 2 investigates how genetic interactions can favor particular combinations of resistance-conferring mutations.
    [Show full text]
  • 2-Amino-1,3,4-Thiadiazoles in Leishmaniasis
    Review Future Prospects in the Treatment of Parasitic Diseases: 2‐Amino‐1,3,4‐Thiadiazoles in Leishmaniasis Georgeta Serban Pharmaceutical Chemistry Department, Faculty of Medicine and Pharmacy, University of Oradea, 29 Nicolae Jiga, 410028 Oradea, Romania; [email protected]; Tel: +4‐0756‐276‐377 Received: 22 March 2019; Accepted: 17 April 2019; Published: 19 April 2019 Abstract: Neglected tropical diseases affect the lives of a billion people worldwide. Among them, the parasitic infections caused by protozoan parasites of the Trypanosomatidae family have a huge impact on human health. Leishmaniasis, caused by Leishmania spp., is an endemic parasitic disease in over 88 countries and is closely associated with poverty. Although significant advances have been made in the treatment of leishmaniasis over the last decade, currently available chemotherapy is far from satisfactory. The lack of an approved vaccine, effective medication and significant drug resistance worldwide had led to considerable interest in discovering new, inexpensive, efficient and safe antileishmanial agents. 1,3,4‐Thiadiazole rings are found in biologically active natural products and medicinally important synthetic compounds. The thiadiazole ring exhibits several specific properties: it is a bioisostere of pyrimidine or benzene rings with prevalence in biologically active compounds; the sulfur atom increases lipophilicity and combined with the mesoionic character of thiadiazoles imparts good oral absorption and good cell permeability, resulting in good bioavailability. This review presents synthetic 2‐amino‐1,3,4‐thiadiazole derivatives with antileishmanial activity. Many reported derivatives can be considered as lead compounds for the synthesis of future agents as an alternative to the treatment of leishmaniasis. Keywords: 2‐amino‐1,3,4‐thiadiazole; neglected tropical diseases; protozoan parasites; Leishmania spp.; antileishmanial activity; inhibitory concentration 1.
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]
  • Use of Antibiotics in Ornamental Fish Aquaculture1 Roy P
    Cir 84 Use of Antibiotics in Ornamental Fish Aquaculture1 Roy P. E. Yanong2 Introduction based on their response to a protocol called gram staining. Gram-positive bacteria stain blue, and gram-negative Antibiotics are very useful additions to any fish-health bacteria stain pink. They stain differently because each manager’s toolbox, but they are only tools and not ‘magic group has a different type of outer structure known as the bullets.’ The ability of antibiotics to help eliminate a fish cell wall. This difference is important for the producer disease depends on a number of factors: 1) Does the and aquaculturist because some antibiotics work better problem actually have a bacterial component? 2) Are the against gram-positive bacteria and others work better bacteria involved sensitive to the antibiotic chosen? 3) Are against gram-negative bacteria. Most bacteria that infect the proper dosage and treatment intervals being used? 4) fish are gram-negative, including Aeromonas hydrophila, Have other contributing stresses been removed or reduced? Aeromonas salmonicida, Flavobacterium columnare (which causes columnaris), Vibrio, and Pseudomonas species. (See Antibiotics, in and of themselves, do not cure a fish. Antibi- UF/IFAS Fact Sheets FA-14 Aeromonas Infections, FA-31 otics merely control the population growth of bacteria in a Vibrio Infections of Fish and FA-11 Columnaris disease). fish long enough for its immune system to eliminate them. The major group of gram-positive bacteria that cause Before antibiotics are even considered, sources of stress disease in fish are Streptococcus. (See UF/IFAS Circular 57 such as poor water quality (including drastic temperature Streptococcal Infections in Fish.) change), nutrition, genetics, and handling or transport must A third group, the acid-fast bacteria, which includes be removed or reduced.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis
    separations Review On the Extraction of Antibiotics from Shrimps Prior to Chromatographic Analysis Victoria Samanidou *, Dimitrios Bitas, Stamatia Charitonos and Ioannis Papadoyannis Laboratory of Analytical Chemistry, University of Thessaloniki, GR 54124 Thessaloniki, Greece; [email protected] (D.B.); [email protected] (S.C.); [email protected] (I.P.) * Correspondence: [email protected]; Tel.: +30-2310-997698; Fax: +30-2310-997719 Academic Editor: Frank L. Dorman Received: 2 February 2016; Accepted: 26 February 2016; Published: 4 March 2016 Abstract: The widespread use of antibiotics in veterinary practice and aquaculture has led to the increase of antimicrobial resistance in food-borne pathogens that may be transferred to humans. Global concern is reflected in the regulations from different agencies that have set maximum permitted residue limits on antibiotics in different food matrices of animal origin. Sensitive and selective methods are required to monitor residue levels in aquaculture species for routine regulatory analysis. Since sample preparation is the most important step, several extraction methods have been developed. In this review, we aim to summarize the trends in extraction of several antibiotics classes from shrimps and give a comparison of performance characteristics in the different approaches. Keywords: sample preparation; extraction; aquaculture; shrimps; chromatography; antibiotics 1. Introduction According to FAO (CWP Handbook of Fishery Statistical Standards, Section J: AQUACULTURE), “aquaculture is the farming of aquatic organisms: fish, mollusks, crustaceans, aquatic plants, crocodiles, alligators, turtles, and amphibians. Farming implies some form of intervention in the rearing process to enhance production, such as regular stocking, feeding, protection from predators, etc.”[1]. Since 1960, aquaculture practice and production has increased as a result of the improved conditions in the aquaculture facilities.
    [Show full text]